LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

Search

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

63.34 2.13

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

61.3

Максимум

64

Ключови измерители

By Trading Economics

Приходи

-6.2M

-49M

Продажби

-9.1M

33M

EPS

-0.81

Марж на печалбата

-151.352

Служители

283

EBITDA

-9.5M

-47M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+28.51% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-319M

3.8B

Предишно отваряне

61.21

Предишно затваряне

63.34

Настроения в новините

By Acuity

50%

50%

179 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2025 г., 20:54 ч. UTC

Придобивния, сливания и поглъщания

PNC to Buy Private-Equity Agent Aqueduct Capital

20.05.2025 г., 20:50 ч. UTC

Печалби

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20.05.2025 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20.05.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20.05.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20.05.2025 г., 23:08 ч. UTC

Пазарно говорене

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20.05.2025 г., 22:45 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20.05.2025 г., 22:44 ч. UTC

Топ новини

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20.05.2025 г., 22:20 ч. UTC

Топ новини

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Adj EPS 36c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q EPS 10c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Sales $972M >JHX

20.05.2025 г., 20:52 ч. UTC

Топ новини

Elon Musk to Cut Back Political Spending -- 3rd Update

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20.05.2025 г., 20:28 ч. UTC

Придобивния, сливания и поглъщания

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20.05.2025 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.29 >XP

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Rev BRL4.345B >XP

20.05.2025 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20.05.2025 г., 20:20 ч. UTC

Топ новини

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20.05.2025 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20.05.2025 г., 20:11 ч. UTC

Топ новини

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20.05.2025 г., 20:09 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

28.51% нагоре

12-месечна прогноза

Среден 82.08 USD  28.51%

Висок 94 USD

Нисък 72 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

12

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

179 / 382 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.